Dr. Margaret Jackson, DPhil
Head of Preclinical R&D, Juvenescence
I’m delighted to join the mission of Juvenescence where we will accelerate the discovery and development of novel therapeutics in service of longevity and healthy aging
Dr. Margaret Jackson, DPhil is Vice President and Head of Preclinical R&D at Juvenescence. She has authored over 40 scientific papers and patents as a neuropharmacology leader with almost 20 years of drug discovery experience and an awardee of several NIH Small Business Innovation Research Awards.
“I’m delighted to join the mission of Juvenescence where we will accelerate the discovery and development of novel therapeutics in service of longevity and healthy aging,” Dr. Jackson states.
Dr. Jackson is Founder and CEO of BYOMass Inc. and is CEO and Board Chairwoman of Napa Therapeutics. She has a successful track record of initiating and developing multiple small molecule and biologic programs from idea to Phase II clinical studies. Within a 15-year career at Pfizer, she led multiple groups across 4 disease areas and 3 research sites within the UK and US.
Dr. Jackson served on the Cardiovascular Metabolic Disease Leadership team at Pfizer. As Head of Eating Disorders at Pfizer, her group specialized in hypothalamic control of caloric intake, resulting in 2 novel clinical candidates and an innovative early portfolio. As a member of the Emerging Science and Technology Fund committee within Pfizer, she was responsible for assessing external collaborations and seed investments across cardiovascular metabolic diseases, oncology, inflammation/immunology, neuroscience, chemistry, biotherapeutics, pharmaceutical sciences, and drug safety.
Dr. Jackson has a DPhil. in neuropharmacology from Oxford University in the UK. She was awarded a Royal Society Postdoctoral Fellowship at the University of Melbourne in Australia.
Outside of work, Dr. Jackson has a passion for the outdoors: traveling, camping and anything she can do with her husband and two boys.